Ascendiant Capital Markets Cuts Vivos Therapeutics (NASDAQ:VVOS) Price Target to $6.20

by · The Cerbat Gem

Vivos Therapeutics (NASDAQ:VVOS – Free Report) had its price objective cut by Ascendiant Capital Markets from $6.60 to $6.20 in a research report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Alliance Global Partners reissued a “buy” rating on shares of Vivos Therapeutics in a research report on Tuesday, April 1st.

Get Our Latest Stock Analysis on VVOS

Vivos Therapeutics Stock Up 1.0 %

Shares of NASDAQ:VVOS opened at $2.10 on Tuesday. Vivos Therapeutics has a fifty-two week low of $1.91 and a fifty-two week high of $6.28. The stock has a market cap of $12.37 million, a price-to-earnings ratio of -0.37 and a beta of 7.31. The firm’s 50 day moving average price is $3.14 and its 200 day moving average price is $3.53.

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.15. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $3.89 million. Vivos Therapeutics had a negative net margin of 86.19% and a negative return on equity of 335.04%. On average, equities analysts anticipate that Vivos Therapeutics will post -1.79 EPS for the current year.

Institutional Investors Weigh In On Vivos Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VVOS. Commonwealth Equity Services LLC increased its position in shares of Vivos Therapeutics by 23.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock worth $112,000 after purchasing an additional 5,000 shares in the last quarter. Cutter & CO Brokerage Inc. purchased a new position in Vivos Therapeutics during the 4th quarter worth approximately $163,000. Geode Capital Management LLC increased its position in Vivos Therapeutics by 55.6% during the fourth quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock worth $192,000 after buying an additional 16,025 shares during the period. Finally, Anson Funds Management LP acquired a new stake in shares of Vivos Therapeutics in the fourth quarter valued at approximately $1,041,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

Vivos Therapeutics Company Profile

(Get Free Report)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Recommended Stories